Τίτλος:
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia is a deadly disease with no effective treatment. The purpose of this randomised prospective multicentric study was to characterise the clinical effects of interferon gamma (IFN-γ) 1b administered subcutaneously thrice weekly versus colchicine for 2 yrs. This study had no pre-specified end-points. Fifty consecutive IPF patients were randomised. Patients with mild-to-moderate IPF were eligible for the study if they had histologically proven IPF, or, in the absence of surgical biopsy, fulfilled the European Respiratory Society/American Thoracic Society criteria. In the intent-to-treat population, five out of 32 (15.6%) IFN-γ-1b patients and seven out of 18 (38.8%) colchicine patients died after a median follow-up period of 25 months Patients treated with IFN-γ 1b showed a better outcome after 2 yrs of therapy, and fewer symptoms, as assessed using the St George's Respiratory Questionnaire, after 12 months of therapy. Also, the IFN-γ-1b group exhibited a higher forced vital capacity (percentage of the predicted value) after 24 months of treatment. No significant differences were detected in resting arterial oxygen tension, total lung capacity (% pred), transfer factor of the lung for carbon monoxide (% pred) and high-resolution computed tomographic scoring between the two treatment groups. These data suggest that long-term treatment with interferon gamma 1b may improve survival and outcome in patients with mild-to-moderate idiopathic pulmonary fibrosis. Further studies are needed to verify these results. Copyright ©ERS Journals Ltd 2006.
Συγγραφείς:
Antoniou, K.M.
Nicholson, A.G.
Dimadi, M.
Malagari, K.
Latsi, P.
Rapti, A.
Tzanakis, N.
Trigidou, R.
Polychronopoulos, V.
Bouros, D.
Περιοδικό:
The European respiratory journal
Λέξεις-κλειδιά:
carbon monoxide; colchicine; gamma1b interferon; prednisolone, adult; aged; arterial oxygen tension; article; clinical trial; computer assisted tomography; controlled clinical trial; controlled study; diarrhea; disease severity; drug dose reduction; drug dose regimen; drug efficacy; drug safety; drug tolerability; drug withdrawal; female; fever; flu like syndrome; follow up; forced expiratory volume; headache; histopathology; human; human tissue; idiopathic disease; long term care; low drug dose; lung biopsy; lung fibrosis; major clinical study; male; mortality; multicenter study; myalgia; outcome assessment; patient assessment; practice guideline; prediction; priority journal; questionnaire; randomized controlled trial; respiratory tract infection; rigor; symptom; total lung capacity; treatment duration, Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colchicine; Female; Humans; Interferon-gamma, Recombinant; Male; Middle Aged; Pulmonary Fibrosis; Respiratory Function Tests; Treatment Outcome; Tubulin Modulators
DOI:
10.1183/09031936.06.00032605
